European Psychiatry - Volume 41 - April 2017

374 / 916

S370 25th European congress of psychiatry / European Psychiatry 41S (2017) S365–S404
come in schizophrenia. A helpful approach to promote adherence
in schizophrenia is the use of long-acting injectable (LAI) antipsy-
chotics.
Object To evaluate:
– the global functioning and the hospitalization rate occurred in
the year before and in the year following the switch from a low-
efficacy oral antipsychotic to either a LAI once-monthly therapy
(palmitate paliperidone or olanzapine pamoate) or the correspond-
ing oral compound (paliperidone\risperidone or olanzapine) in
schizophrenic patients;
– the treatment attitude and the insight in patients treated with
second-generation antipsychotic (SGA)-LAIs and with the corre-
sponding oral compounds.
Method Sixty adult schizophrenic outpatients: thirty were
switched to LAIs and thirty to the corresponding oral antipsychotic.
We used the following scales: DrugAttitude Inventory (DAI), Sched-
ule for the Assessment of Insight (SAI), Life Skill Profile (LSP).
Results Number of hospitalizations per year decreased in both
groups (LAIs: from 1.3 ± 0.5 to 0.3 ±0.5; oral: from 1.3 ± 0.5 to
0.6 ± 0.5). We found a direct association between the “hospitaliza-
tion event” and the oral drug compared to the corresponding LAI
formulation (P= 0.049; OR: 3.05; 95% IC: 1.01–9.26). Patient receiv-
ing LAIs achieved a more significant improvement at the LSP score
compared to the oral group (P < 0.001 vs. P= 0.0034) and higher DAI
(5.9 ± 4.3 vs. −1.1 ±4.3) and SAI (8.7 ±2.9 vs. 5.6 ± 2.1).
Conclusions Our data suggest that SGA-LAIs, improving the
adherence to the treatment, may sensitively reduce costs in mental
health services.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0765
Analysis of big data shows haloperidol
with a decreased level of serum
potassium
J.S. Noh ∗ . Park . Lim
1 Ajou University School of Medicine, Department of Psychiatry,
Suwon, Republic of Korea
2 Mibyeong Research Center, Korea Institute of Oriental Medicine,
Daejeon, Republic of Korea
∗ Corresponding author.
Introduction Haloperidol has been used for the treatment of
schizophrenic disorders and other disorders with psychotic symp-
toms in psychiatric cares. It has been reported that haloperidol
can cause QT-prolongation as well as Torsades de Pointes, espe-
cially in hypokalemic condition. Here, we tested the usefulness
of the large clinical electronic medical record system data from
a hospital located in South Korea and further investigated any
change in potassium levels before and after an exposure to
haloperidol.
Methods The dataset used in this study is derived from open
access database with information such as admission, discharge,
diagnosis, prescribed drugs and selected laboratory data for the
period 1 June 1994 to 31 July 2013. This database contains infor-
mation of total 461,170 patients with 4,920,758 prescriptions and
3,811,812 data about serum potassium levels.
Results Extracting a dataset from this database to compare the
levels of serum potassium before and after haloperidol usage, we
selected 3661 cases of data, 2476 of them (67.6%) were males and
1185 (32.4%) were females. More than 98.5% (3606) was Asians,
and mean age of the patients was 68.63 ± 17.3 years old. The lev-
els of serum potassium before and after haloperidol usage were
4.93 ± 2.53 and 3.86 ±0.6mEq/L, respectively, and t-tests revealed
that those levels were significantly different (< 0.001).
Conclusions Findings showed that an exposure to haloperidol
could lead to a decrease in levels of serumpotassium. We suggested
that EMR data can be a valuable tool to investigate the effects of
treatment on several clinical data.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0766
Effectiveness and tolerance of
treatment with Aripiprazole LAI in a
group of schizophrenics patients
N. Olmo López (Psychiatrist) ∗ García Nicolás (Psychiatrist)
L.A. Nú˜nez Domínguez (Psychiatrist)
1 Mental Health Centre, Navarra, Tudela, Spain
2 Medical Center, Navarra, Pamplona, Spain
∗ Corresponding author.
Introduction In the pharmacological treatment of schizophrenia,
more and more authors suggesting the use of injectable antipsy-
chotics long-term these patients, since it increases adherence to
treatment, one of the risk factors for relapse that argues most often
to explain the failure of the treatment of these patients.
In the present study, it is to observe the evolution of a group of
such patients to assess efficacy and tolerability of treatment with
Aripiprazole LAI.
Material and method Data from 17 patients treated at a men-
tal health center in Navarra (Spain), diagnosed with schizophrenic
disorder, followed over a year after beginning treatment with Arip-
iprazol LAI are collected.
The data collected are:
– date of treatment change (month and year);
– antipsychotic previous;
– reason for change;
– aripiprazole LAI dose;
– number of income before and after the start of Aripiprazole LAI
(mirror);
– effects adverse pre and post start of treatment with Aripiprazole
LAI: metabolic, endocrine, extrapyramidal;
– treatment antipsychotic concomitant pre and post start Aripipra-
zole LAI.
Results The results show a decrease in the number of income
after the start with Aripiprazole LAI, with very good retention of
treatment, and a low number of side effects, which were mild.
Conclusions Treatment with Aripiprazole LAI is a good therapeu-
tic alternative to the use of antipsychotic drugs by mouth, with
good adherence, tolerability and efficacy.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0767
The new target therapy to prevent
weight gain associated to atypical
antipsychotics: PKC
C. Pavan ∗, A. Rimessi , B. Zavan , V. Vindigni , P. Pinton
1 University of Padova, Department of Medicine, Padova, Italy
2 University of Ferrara, 2aDepartment of Morphology, Surgery and
Experimental Medicine, Section of Pathology, Oncology and
Experimental Biology, Laboratory for Technologies of Advanced
Therapies LTTA, Ferrara, Italy
3 University of Padova, Department of Biomedical Sciences, Padova,
Italy
4 University of Padova, Department of Neurosciences, Padova, Italy
∗ Corresponding author.
Antipsychotic drugs are currently used in clinical practice for a vari-
ety of mental disorders. Clozapine is the most effective medication
for treatment-resistant schizophrenia, in controlling aggression